Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs)-Reference-Cited by-同舟云学术

Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs)

Published:2011-02-11 Issue:2 Volume:128 Page:553-561
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Oberguggenberger Anne,Hubalek Michael,Sztankay Monika,Meraner Verena,Beer Beate,Oberacher Herbert,Giesinger Johannes,Kemmler Georg,Egle Daniel,Gamper Eva-Maria,Sperner-Unterweger Barbara,Holzner Bernhard

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-011-1378-5.pdf

Reference38 articles.

1. Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451–1467

2. Jonat W, Gnant M, Boccardo F et al (2006) Effectiveness of switching from adjuvant tamoxifen to anastrazole in postmenopausal women with hormone-sensitive early-stage breast cancer. Lancet Oncol 7:991–996

3. Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365(9453):60–62

4. The Breast International Group 1-98 Collaborative Group (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353(26):2747–2757

5. Cuzick J, Sestak I, Baum M et al (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11(12):1135–1141. doi: 10.1016/S1470-2045(10)70257-6

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of a physiotherapy, yoga and patient education programme for patients with breast cancer and hormone therapy-induced pain: a multicentre randomised study protocol (SKYPE 2);BMJ Open;2024-01

2. Development and Evaluation of a Remote Monitoring Regional Adjuvant Abemaciclib Service for Patients with High-Risk Early Breast Cancer;2024

3. Feasibility of Symptom Monitoring During the First Year of Endocrine Therapy for Early Breast Cancer Using Patient-Reported Outcomes Collected via Smartphone App;JCO Oncology Practice;2023-11

4. Aromatase Inhibitor–Related Symptoms Reported by Postmenopausal Women with Nonmetastatic, Estrogen Receptor–Positive Breast Cancer: A Systematic Review;Seminars in Oncology Nursing;2023-10

5. Adherence to hormonal therapy after surgery among older women with ductal carcinoma in situ: Implications for breast cancer–related adverse health events;Cancer;2023-09-26